Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Calcium homeostasis modulator protein 2 (CALHM2) is a membrane-bound, large-pore ion channel belonging to the CALHM family. It forms oligomeric assemblies, typically as an 11-mer, and is predicted to enable monoatomic cation channel activity. CALHM2 mediates ATP release from astrocytes and regulates ATP-induced Ca²⁺ influx in microglia, modulating neuronal ATP and calcium homeostasis, synaptic transmission, and neuroinflammatory responses. The protein may also form intercellular gap junction-like structures and is implicated in the regulation of apoptosis. CALHM2 is expressed in the central nervous system—especially in glial cells—and linked to the pathophysiology of depression and neurodegenerative diseases such as Alzheimer's disease, with emerging associations to medulloblastoma. Channel gating mechanisms remain incompletely understood, and aside from a report of inhibition by rubidium red, specific drugs targeting CALHM2 are lacking[1][2][3].
Channel inhibition (for rubidium red; other mechanisms currently unknown due to lack of further identified drugs)[1]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Calcium homeostasis modulator protein 2 (CALHM2).